Lifé Pharma chooses IBS Enterprise to automate its supply chain.

Lifé Pharma has signed a contract with IBS Belgium for the implementation of the IBS Enterprise ERP solution for Windows. This cooperation with IBS will enable Lifé Pharma to pursue its development objectives.  The key aims of the project are to streamline logistics flows, improve management of the warehouse and ensure complete traceability.

Robert Walnier, General Manager of Lifé Pharma, talks about his decision: "During the selection process, IBS convinced us of its knowledge of the pharmaceutical distribution business. A long list of references testified to the company's expertise in all aspects of the pharmaceutical industry.  IBS has proven to be a real partner who will help us to optimise our working procedures."

"We supply more than 300 pharmacies in the Wallonia region of Belgium from our 4,500 m² warehouse stocking around 20,000 products. Our current information system is preventing us from optimising our activities. IBS Enterprise will provide us with a precise view of our stocks and suitable tools to allow us to analyse and take any required action. It will also support the development of our e-commerce business."

Steven Thornton, Executive VP Enterprise Software at IBS, adds: "In the past, IBS has worked mainly with the iSeries platform, however our commitment with Lifé Pharma shows that our solution is completely compatible with Windows technology."

The IBS FasTraX methodology will also be used. Robert Walnier emphasises: "Thanks to this methodology, the solution will be up and running within 7 months. This represents significant added value, in particular in terms of ROI."

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.